Literature DB >> 7794066

Results of pancreas transplantation with portal venous and enteric drainage.

A O Gaber1, M H Shokouh-Amiri, D K Hathaway, L Hammontree, A E Kitabchi, L W Gaber, M F Saad, L G Britt.   

Abstract

PURPOSE: The standard method for pancreatic transplantation involves drainage of exocrine secretions into the urinary bladder with venous outflow into the systemic circulation. Despite the high success rate associated with this approach, it often leads to complications, including chemical cystitis, reflux pancreatitis, metabolic acidosis, and hyperinsulinemia. The authors developed a new technique of pancreatic transplantation with portal drainage of endocrine secretions and enteric drainage of exocrine secretions (PE), which theoretically should be more physiologic. PROCEDURES: All patients were insulin-dependent diabetics with end-stage renal disease who underwent combined kidney-pancreas transplantation. Between 1990 and 1994, 19 patients have been transplanted using intraperitoneal placement of the pancreas allograft with exocrine drainage into a Roux-en Y loop and venous drainage into the portal circulations (PE). A comparison group of all patients undergoing standard systemic-bladder (SB) transplantation between April 1989 and March 1993 (n = 28) also was studied. Patient follow-up ranges from 6 months to 5 years for the SB patients (mean = 2.5 years) and 6 months to 4 years for the PE patients (mean = 1.6 years). Routine follow-up includes documentation of the clinical course and detailed endocrine studies.
FINDINGS: Patient and graft actuarial survival at 1 and 3 years is no different for SB and PE patients. Urinary tract infections occurred in 89.3% of the SB patients (2.8/patient) versus 26.3% of the PE patients (0.25/patient, p < or = 0.0001). None of the PE patients experienced hematuria compared with 53.6% of the SB patients (p < or = 0.0001); however, two PE patients had melanotic episodes. The incidence of urinary retention and reflux pancreatitis was 32.1% versus 5.3% (p < or = 0.028) for SB and PE groups, respectively. Patients in the SB group required sodium bicarbonate therapy (mean = 55 mEq/day) although no PE patient required routine therapy; despite this, SB patients experienced more episodes of acidosis (44 vs. 5). Endocrine studies indicate no difference in glycosylated hemoglobin or fasting and stimulated glucose values throughout the follow-up period. In contrast, hyperinsulinemia was evident in both fasting and stimulated tests for the SB patients, with values consistently two- to fivefold higher than those of the PE group.
CONCLUSIONS: These results indicate that PE and SB pancreas transplantation are equivalent in terms of patient and graft survival and suggest that the PE approach is associated with a decreased incidence of metabolic and bladder-related complications. In addition, the PE approach eliminates the state of peripheral hyperinsulinemia that characterizes the SB procedure. Continued follow-up will be necessary to determine if long-term outcomes will differ for patients with PE and SB grafts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794066      PMCID: PMC1234682          DOI: 10.1097/00000658-199506000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells.

Authors:  R W Stout; E L Bierman; R Ross
Journal:  Circ Res       Date:  1975-02       Impact factor: 17.367

2.  Complications of pancreas transplantation-effect of technique.

Authors:  L H Toledo-Pereyra; V K Mittal
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Paratopic segmental pancreas grafting: a technique with portal venous drainage.

Authors:  R Y Calne
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  The relationship of glucose disappearance rate (kG) to acute pancreas allograft rejection.

Authors:  D S Elmer; D K Hathaway; H Shokouh-Amiri; T Hughes; A O Gaber
Journal:  Transplantation       Date:  1994-05-15       Impact factor: 4.939

5.  Improvement in quality of life reported by diabetic recipients of kidney-only and pancreas-kidney allografts.

Authors:  D K Hathaway; M S Hartwig; J Milstead; D Elmer; S Evans; A O Gaber
Journal:  Transplant Proc       Date:  1994-04       Impact factor: 1.066

6.  Segmental pancreatic transplantation with enteric exocrine diversion.

Authors:  C G Groth; G Tydén; G Lundgren; H Wilczek; G Klintmalm; L Ost; R Gunnarsson; J Ostman
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

Review 7.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

8.  The effects of hyperinsulinemia on arterial wall and peripheral muscle metabolism in dogs.

Authors:  K Falholt; R Cutfield; R Alejandro; L Heding; D Mintz
Journal:  Metabolism       Date:  1985-12       Impact factor: 8.694

9.  Metabolic effects of urinary diversion of exocrine secretions in pancreatic transplantation.

Authors:  D D Nghiem; T A Gonwa; R J Corry
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

10.  The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes.

Authors:  R W Bilous; S M Mauer; D E Sutherland; J S Najarian; F C Goetz; M W Steffes
Journal:  N Engl J Med       Date:  1989-07-13       Impact factor: 91.245

View more
  15 in total

1.  Superiority of portal venous drainage over systemic venous drainage in pancreas transplantation: a retrospective study.

Authors:  B Philosophe; A C Farney; E J Schweitzer; J O Colonna; B E Jarrell; V Krishnamurthi; A M Wiland; S T Bartlett
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

Review 2.  Exocrine drainage in vascularized pancreas transplantation in the new millennium.

Authors:  Hany El-Hennawy; Robert J Stratta; Fowler Smith
Journal:  World J Transplant       Date:  2016-06-24

3.  A prospective comparison of simultaneous kidney-pancreas transplantation with systemic-enteric versus portal-enteric drainage.

Authors:  R J Stratta; M H Shokouh-Amiri; M F Egidi; H P Grewal; A T Kizilisik; N Nezakatgoo; L W Gaber; A O Gaber
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

4.  Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction.

Authors:  R J Stratta; A O Gaber; M H Shokouh-Amiri; K S Reddy; R R Alloway; M F Egidi; H P Grewal; L W Gaber; D Hathaway
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

5.  Pancreas transplantation.

Authors:  Duck Jong Han; David Er Sutherland
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

Review 6.  Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?

Authors:  Francesca M Egidi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Simultaneous cadaver pancreas living-donor kidney transplantation: a new approach for the type 1 diabetic uremic patient.

Authors:  A C Farney; E Cho; E J Schweitzer; B Dunkin; B Philosophe; J Colonna; S Jacobs; B Jarrell; J L Flowers; S T Bartlett
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

8.  Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy.

Authors:  S T Bartlett; E J Schweitzer; L B Johnson; P C Kuo; J C Papadimitriou; C B Drachenberg; D K Klassen; E W Hoehn-Saric; M R Weir; A L Imbembo
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 9.  Evolving surgical strategies for pancreas transplantation.

Authors:  David B Leeser; Stephen T Bartlett
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

10.  Pancreatic Transplantation: Beta Cell Replacement.

Authors:  David L. Bigam; AM James Shapiro
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.